| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PKC alpha; PKC beta; PKC delta; PKC epsilon; PKC gamma; PKC zeta; PKC-A; PKC-alpha; PKC2; PKCA; PKCB; PKCD; PKCE; PKCG; PRKCA; PRKCB; PRKCB1; PRKCB2; PRKCD; PRKCE; PRKCG; PRKCZ; Protein kinase C alpha; Protein kinase C alpha type; Protein kinase C; Protein kinase C beta; Protein kinase C delta; Protein kinase C epsilon; Protein kinase C gamma; Protein kinase C zeta;;PKC |
| WB Predicted band size | Calculated MW: 37,40,68-84 kDa ; Observed MW: 77 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PKC |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4篇关于PKC抗体的参考文献示例(内容为模拟，仅供参考)：
1. **"Protein Kinase C Isozymes and Substrate Specificity in Cellular Signaling"**
- **作者**: Alex Toker 等
- **摘要**: 综述PKC不同异构体的结构差异及功能，探讨特异性抗体在检测亚细胞定位和激活状态中的应用，强调抗体在区分PKCα、β、γ等异构体中的关键作用。
2. **"Targeting PKCδ in Cardiac Ischemia-Reperfusion Injury: Role of Selective Antibodies"**
- **作者**: Daria Mochly-Rosen 等
- **摘要**: 研究PKCδ在心肌缺血再灌注损伤中的病理机制，开发特异性抗体阻断其活化，证明抗体干预可减少细胞凋亡并改善心脏功能。
3. **"PKCε Overexpression in Cancer: Validation by Immunohistochemistry and Therapeutic Implications"**
- **作者**: Peter J. Parker 等
- **摘要**: 通过免疫组化分析多种肿瘤中PKCε的异常表达，验证高特异性抗体的可靠性，并探讨其作为预后标志物或治疗靶点的潜力。
4. **"Structural Insights into PKCα Activation and Antibody Design"**
- **作者**: Susan S. Taylor 等
- **摘要**: 利用X射线晶体学解析PKCα的活化构象，基于此设计单克隆抗体，证明其可选择性抑制PKCα的膜转位及下游信号通路。
(注：以上文献名为虚拟生成，实际引用请通过PubMed或Google Scholar检索验证。)
Protein kinase C (PKC) antibodies are essential tools for studying the PKC family of serine/threonine kinases, which play pivotal roles in cellular signaling pathways. PKC enzymes regulate diverse processes, including cell proliferation, differentiation, apoptosis, and immune responses. The PKC family consists of multiple isoforms (e.g., PKC-α, -β, -γ, -δ), categorized into classical, novel, and atypical subfamilies based on their activation mechanisms. Dysregulation of PKC activity is linked to cancers, neurological disorders, and metabolic diseases, driving interest in their molecular functions.
PKC antibodies are designed to detect specific isoforms or phosphorylation states, enabling researchers to analyze expression levels, localization, and activation status in tissues or cells. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Selective antibodies help elucidate isoform-specific roles, such as PKC-δ in apoptosis or PKC-β in diabetic complications. Additionally, PKC inhibitors/activators are explored as therapeutics, making these antibodies critical for validating drug targets and understanding mechanisms in preclinical models.
Challenges include cross-reactivity due to isoform homology, necessitating rigorous validation. Advances in monoclonal antibody technology have improved specificity, supporting precise research into PKC-related pathologies and signaling networks.
×
